Clinical Scorecard: Stuart Therapeutics Expands Corneal Repair Pipeline
At a Glance
| Category | Detail |
|---|---|
| Condition | Corneal wounds and ocular surface damage; ST-100 is also being investigated for dry eye disease. |
| Key Mechanisms | ST-100 (vezocolmitide) is an investigational collagen mimetic peptide developed using PolyCol™ technology and designed to target and repair damaged helical collagen in the ocular extracellular matrix. |
| Target Population | Planned studies will assess corneal wounds related to surgery, trauma, ulcers, and chemical burns. |
| Care Setting | Investigational clinical research in ophthalmology; efficacy for corneal wound healing has not been established. |
Key Highlights
- Stuart Therapeutics submitted an IND application amendment to the FDA to study ST-100 for corneal wound healing.
- The planned proof-of-concept study would be the first expansion of ST-100 development beyond dry eye disease.
- A phase 2 trial assessing several types of corneal wounds is planned for the second half of 2027.
- Earlier phase 2 and initial phase 3 DED studies involving more than 250 patients reported improvements in corneal fluorescein staining and some symptom-related outcomes.
- The initial phase 3 DED trial did not meet its primary endpoint for statistically significant improvement in Schirmer's tear test responder rates versus vehicle.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
- Efficacy of ST-100 for corneal wound healing remains to be established.
- The initial phase 3 DED trial did not meet its primary endpoint.
Patient & Prescribing Data
No approved use for corneal wound healing is established; planned studies will evaluate patients with corneal wounds related to surgery, trauma, ulcers, and chemical burns.
ST-100 is investigational for corneal wound healing; the announcement provides no approved dose or prescribing instructions.
Clinical Best Practices
- The source states that ST-100's efficacy in corneal wound healing remains to be established.
- The reported DED study outcomes concern dry eye disease; efficacy for corneal wound healing remains unestablished.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
